Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430489 | 0.87 | PTGER4 (0.47) | KITBRAFPTGER4CNR1RAB9A | |
| SCHEMBL3426277 | 0.86 | RAB9A (0.57) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL3432205 | 0.86 | RAB9A (0.51) | IDH1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3431802 | 0.86 | PTGER4 (0.46) | KITBRAFPTGER4CNR1RAB9A | |
| SCHEMBL3755332 | 0.85 | KDM4E (0.54) | IDH1MCL1PTGER4KDM4EMEN1 | |
| SCHEMBL3430168 | 0.84 | RAB9A (0.46) | KITBRAFPTGER4KDM4ECNR1 | |
| SCHEMBL3430801 | 0.83 | MAPT (0.54) | IDH1MCL1PTGER4KDM4EMEN1 | |
| SCHEMBL3427738 | 0.83 | MCL1 (0.59) | IDH1MCL1PTGER4KDM4EMEN1 | |
| SCHEMBL3431404 | 0.83 | IDH1 (0.49) | IDH1MCL1PTGER4KDM4EMEN1 | |
| SCHEMBL3428417 | 0.83 | PTGER4 (0.57) | IDH1MCL1PTGER4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | claimed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | claimed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | claimed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | IDH1 1584/4885MCL1 4336/4885KIT 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.